Here we discuss the dramatic cutaneous reactions of two patients receiving targeted
therapies for cancer (one on a MEK inhibitor/BRAF inhibitor and the other receiving
carfilzomib). Demodicosis was the underlying cause in both cases, though the infection was
mistaken for a reaction to the patients' complex malignancy therapies. Given the prevalence
of cutaneous side effects of chemotherapy and targeted cancer therapies and the protean
nature of demodicosis, it follows that demodicosis may be easily mistaken as a drug reaction …